BR112015013387B8 - Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas - Google Patents

Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas

Info

Publication number
BR112015013387B8
BR112015013387B8 BR112015013387A BR112015013387A BR112015013387B8 BR 112015013387 B8 BR112015013387 B8 BR 112015013387B8 BR 112015013387 A BR112015013387 A BR 112015013387A BR 112015013387 A BR112015013387 A BR 112015013387A BR 112015013387 B8 BR112015013387 B8 BR 112015013387B8
Authority
BR
Brazil
Prior art keywords
coiled
modified
improved properties
protein
coil
Prior art date
Application number
BR112015013387A
Other languages
English (en)
Other versions
BR112015013387A2 (pt
BR112015013387B1 (pt
Inventor
Del Campo Ascarateil Judith
Turki Hani Imene
Hill Fergal
Original Assignee
Osivax Sas
Imaxio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osivax Sas, Imaxio filed Critical Osivax Sas
Publication of BR112015013387A2 publication Critical patent/BR112015013387A2/pt
Publication of BR112015013387B1 publication Critical patent/BR112015013387B1/pt
Publication of BR112015013387B8 publication Critical patent/BR112015013387B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

PROTEÍNAS TIPO ESPIRAL ENROLADA MODIFICADAS POSSUINDO PROPRIEDADES MELHORADAS. O presente pedido de patente está relacionado com uma proteína modificada, que compreende uma proteína possuindo um domínio de espiral enrolada e um peptídeo possuindo a sequência tal como apresentada em SEQ ID NO 1: ZXBBBBZ que está ligado ao domínio de espiral enrolada em que: ? Z é qualquer aminoácido ou está ausente; ? X é qualquer aminoácido; ? B é uma arginina (R) ou uma lisina (K). A referida proteína modificada é, em particular, um antígeno ou uma proteína transportadora associada a um antígeno. Esta proteína modificada tem uma maior afinidade para os polímeros carregados negativamente, tais como ácidos nucleicos ou a heparina, e mostra uma imunogenicidade aumentada.
BR112015013387A 2012-12-11 2013-12-11 Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas BR112015013387B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12306560 2012-12-11
EP12306560.9 2012-12-11
US201361802836P 2013-03-18 2013-03-18
US61/802,836 2013-03-18
PCT/EP2013/076289 WO2014090905A1 (en) 2012-12-11 2013-12-11 Modified coiled coil type proteins having improved properties

Publications (3)

Publication Number Publication Date
BR112015013387A2 BR112015013387A2 (pt) 2017-11-14
BR112015013387B1 BR112015013387B1 (pt) 2022-12-20
BR112015013387B8 true BR112015013387B8 (pt) 2023-01-10

Family

ID=47458800

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015013387A BR112015013387B8 (pt) 2012-12-11 2013-12-11 Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas

Country Status (12)

Country Link
US (1) US9388225B2 (pt)
EP (1) EP2931896B1 (pt)
JP (1) JP6518193B2 (pt)
KR (1) KR102237130B1 (pt)
CN (1) CN104981541B (pt)
AU (1) AU2013357367B2 (pt)
BR (1) BR112015013387B8 (pt)
CA (1) CA2893120C (pt)
MX (1) MX363443B (pt)
PL (1) PL2931896T3 (pt)
RU (1) RU2677799C2 (pt)
WO (1) WO2014090905A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520534A (ja) 2013-03-18 2016-07-14 イマクシオＩｍａｘｉｏ インフルエンザ核タンパク質ワクチン
WO2015164798A1 (en) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
RU2732013C1 (ru) * 2019-12-11 2020-09-10 Федеральное бюджетное учреждение науки "Государственный научный центр прикладной микробиологии и биотехнологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ПМБ) Способ сенсибилизации планшета для иммуноферментного анализа нерастворимыми белковыми антигенами
KR102613348B1 (ko) * 2020-01-07 2023-12-13 에이치케이이노엔 주식회사 알부민 및 코일드코일 형성 도메인이 연결된 융합단백질, 및 이를 이용한 이중 표적 결합체
CA3230305A1 (en) 2021-08-24 2023-03-02 Osivax Belgique Immunogenic compositions and their use
WO2023117742A1 (en) 2021-12-22 2023-06-29 Osivax Vaccine compositions and their use
WO2023180394A1 (en) 2022-03-22 2023-09-28 Osivax Mrna vaccine compositions and their use
NL2031833B1 (en) 2022-05-11 2023-11-17 Univ Leiden Immunotherapeutic compositions and adjuvants
CN115779079A (zh) * 2022-10-01 2023-03-14 中国人民解放军军事科学院军事医学研究院 一种可增强与佐剂协同免疫效力的电荷调控型抗原蛋白

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012036A1 (en) * 1997-09-04 1999-03-11 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
EA200201077A1 (ru) * 2000-04-07 2003-04-24 Юниверсити Оф Лидз Инновэйшнз Лимитед Коровые антигенные химерные белки гепатита в
US7270921B2 (en) * 2002-02-08 2007-09-18 Kabushiki Kaisha Toshiba Pattern writing and forming method
WO2004070012A2 (en) * 2003-02-03 2004-08-19 Palo Alto Institute Of Molecular Medicine Cell-killing molecules and methods of use thereof
EP1648500B1 (en) * 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
WO2005077976A2 (en) 2004-02-13 2005-08-25 Avidis Sa Coiled-coil domains from c4b-binding protein
EP1953550A4 (en) * 2005-11-10 2010-04-14 Nat University Of Corp Hiroshi METHOD AND AGENT FOR IMMOBILIZATION OF A PROTEIN BY FIXING THE PROTEIN ON A SUBSTANCE CONTAINING SILICA
EP1795540A1 (en) * 2005-11-30 2007-06-13 Imaxio Multimeric complexes of antigens and an adjuvant
AU2007220988B2 (en) 2006-02-28 2010-06-03 Vaxart, Inc Chimeric adenoviral vectors
GB0706912D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
EP2060586A1 (en) * 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB New synthetic arginine substituted peptides and their use
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
JP2016520534A (ja) * 2013-03-18 2016-07-14 イマクシオＩｍａｘｉｏ インフルエンザ核タンパク質ワクチン

Also Published As

Publication number Publication date
RU2015126105A (ru) 2017-01-18
AU2013357367A1 (en) 2015-06-11
EP2931896A1 (en) 2015-10-21
PL2931896T3 (pl) 2019-07-31
JP2016501266A (ja) 2016-01-18
BR112015013387A2 (pt) 2017-11-14
WO2014090905A1 (en) 2014-06-19
RU2677799C2 (ru) 2019-01-21
KR102237130B1 (ko) 2021-04-08
KR20150094697A (ko) 2015-08-19
EP2931896B1 (en) 2019-01-16
CA2893120C (en) 2022-03-15
US20150093406A1 (en) 2015-04-02
US9388225B2 (en) 2016-07-12
CA2893120A1 (en) 2014-06-19
CN104981541A (zh) 2015-10-14
AU2013357367B2 (en) 2019-10-24
JP6518193B2 (ja) 2019-05-22
BR112015013387B1 (pt) 2022-12-20
WO2014090905A8 (en) 2014-08-21
MX2015007421A (es) 2015-12-07
MX363443B (es) 2019-03-21
CN104981541B (zh) 2022-06-28

Similar Documents

Publication Publication Date Title
BR112015013387B8 (pt) Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas
CY1122691T1 (el) Πρωτεϊνες δεσμευσης αλβουμινης ορου
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
BR112014019901A8 (pt) Proteínas de fator viii recombinante
NZ629394A (en) Synthetic brassica-derived chloroplast transit peptides
TR201908150T4 (tr) Peptitler ve kullanımları.
EA201200515A1 (ru) Полипептиды и их применение
MX2014011600A (es) Proteínas nutritivas, fragmentos y métodos.
ES2625773T3 (es) Genómica de Actinoplanes utahensis
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
EA201401211A1 (ru) Улучшенные варианты фермента химозина
WO2012051498A3 (en) Antibodies that bind amyloid oligomers
EA201390820A1 (ru) Слитый белок против рака
EA201491277A1 (ru) Противораковый слитый белок
BR112016012306A2 (pt) peptídeos ricos em prolina para proteção contra s. pneumoniae
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
EP2589658A4 (en) PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN
BR112016011091A2 (pt) sequência de endolisina kz144 modificada
PE20211303A1 (es) Polipeptidos del factor vii de accion corta
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
TR201902131T4 (tr) Enfeksiyöz bronşit virüsünün (IBV) doku tropizmini uzatan mutant diken proteini.
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
EA201391669A1 (ru) Белок f - новый адгезин haemophilus influenzae, способный связывать ламинин и витронектин
WO2012138176A3 (ko) 타겟 친화도가 유지되고 안정성이 개선된 ｄ-앱타이드 및 레트로 인버소 앱타이드

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: OSIVAX SAS (FR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/12/2013, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2711 DE 20/12/2022 QUANTO AO QUADRO REIVINDICATORIO.